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Abstract:	
Introduction:	Targeted	intraoperative	radiotherapy	(TARGIT	–	IORT)	as	a	tumor	bed	boost	
during	breast	conserving	surgery	is	an	increasingly	used	option	for	women	with	early	breast	
cancer.	In	a	previous	study	our	group	could	show	a	beneficial	effect	of	TARGIT-IORT	on	
overall	survival	after	neoadjuvant	chemotherapy	compared	to	an	external	boost	in	an	
unselected	cohort,	a	result	that	could	not	be	reproduced	in	the	triple	negative	and	HER2	
positive	subgroups.	In	this	study	we	present	the	results	of	a	detailed	subgroup	analysis	of	
the	hormone	receptor	positive	HER2	negative	patients.	
Material	and	methods:	In	this	non-randomized	cohort	study	involving	46	patients	with	
hormone	receptor	positive	HER2	negative	breast	cancer	after	NACT	we	compared	outcomes	
of	21	patients	who	received	a	tumour	bed	boost	with	IORT	(TARGIT-IORT)	during	
lumpectomy	versus	25	patients	treated	in	the	previous	13	months	with	external	(EBRT)	
boost.	All	patients	received	whole	breast	radiotherapy.	Disease	free	survival	(DFS),	overall	
mortality	(OM),	breast-cancer-specific	mortality	(BCSM)	and	non-breast-cancer-specific	
mortality	(NBCSM)	were	compared.		
Results:	There	were	no	statistically	significant	differences	between	the	two	groups	regarding	
tumor	size,	grading,	nodal	status	and	pCR	rates.	Median	follow	up	was	49	months.	Whereas	
DFS	and	BCSM	were	not	significantly	different	between	the	groups,	the	5-year	Kaplan-Meier	
estimate	of	OM	was	significantly	lower	by	21%	with	IORT:	TARGIT-IORT	0	events	(0%),	EBRT	
5	events	(21%),	log	rank	p	=	0.028.	NBCSM	was	significantly	lower	by	16%	with	IORT:	TARGIT-
IORT	0	events	(0%),	EBRT	4	events	(16%),	log	rank	p	=	0,047.	
Conclusion:	Although	our	results	have	to	be	interpreted	with	caution	due	to	the	non-
randomized	nature	and	the	small	size	of	the	cohorts,	we	could	show	that	the	improved	OS	as	
previously	demonstrated	in	our	dataset	for	TARGIT-IORT	during	lumpectomy	after	
neoadjuvant	chemotherapy	as	a	tumor	bed	boost	compared	to	an	external	beam	
radiotherapy	boost	is	driven	by	the	hormone	receptor	positive	HER2	negative	subgroup.	
These	data	give	further	support	to	the	inclusion	of	such	patients	in	the	TARGIT-B	(Boost)	
randomised	trial	that	is	testing	whether	IORT	boost	is	superior	to	EBRT	boost.	
	
Introduction:	
	
Partial	irradiation	of	the	breast	with	TARGIT-	IORT	using	an	intraoperative	dose	of	20	Gray	
(Gy)	with	a	50kV	X-Ray	source	is	an	increasingly	used	option	for	selected	patients	within	a	
risk	adapted	approach	to	replace	whole	breast	irradiation	after	breast	conserving	surgery	for	
breast		cancer	(Sedlmayer	F,	Reitsamer	R,	Wenz	F	et	al.	(2017)	Intraoperative	radiotherapy	
(IORT)	as	boost	in	breast	cancer.	Radiat	Oncol	2017;	12:	23).	Although	the	results	of	the	
TARGIT-A	trial	demonstrated	a	non-inferiority	of	this	approach	after	a	careful	risk	
stratification	1,	the	concept	of	reducing	the	extent	of	radiation	is	not	unopposed	and	
remains	an	issue	of	constant	debate	2.	
	
The	use	of	TARGIT-IORT	as	an	intraoperative	boost	has	been	an	option	for	much	longer.	The	
first	studies	for	the	use	of	this	technique	as	a	replacement	for	the	external	boost	
demonstrated	a	reproducable	local	recurrence	rate	of	1.76	%	after	5	years	rather	than	the	
expected	4.3	%	for	the	external	boost	3	4.	Even	when	used	in	high-risk	patient	cohorts	such	
as	patients	with	triple	negative	(TN)	breast	cancer	in	a	trial	using	electrons	as	an	
intraoperative	radiation	(IOERT)	the	intraoperative	boost	resulted	in	a	favourable	outcome	5.	
However,	although	the	use	of	intraoperative	radiotherapy	as	an	intraoperative	boost	is	
widely	used	in	primary	surgery,	its	use	in	patients	who	undergo	breast	conserving	surgery	
after	neoadjuvant	chemotherapy	is	not	a	standard	yet.	
Neoadjuvant	therapy	has	become	a	standard	of	care	not	only	for	inoperable	or	locally	
advanced	cases	but	also	for	smaller	operable	tumours.	Although	neoadjuvant	chemotherapy	
has	been	proven	to	increase	the	rate	of	breast	conserving	surgeries	this	is	commonly	not	
regarded	as	main	rationale	for	its	use.	Instead,	it	is	commonly	regarded	as	an	option	for	all	
patients	where	systemic	therapy	is	definitely	indicated	at	the	time	of	diagnosis	with	the	goal	
of	improving	disease	free	survival	(DFS)	and	overall	survival	(OS)	6	by	carrying	the	potential	
for	response-guided	treatment	since	allowing	an	in-vivo	observation	of	chemotherapy	
sensitivity	in	an	individual	tumour.	Regimens	used	in	the	neoadjuvant	setting	in	clinical	
practice	are	usually	the	same	as	in	adjuvant	therapy.	
Use	of	chemotherapy	and	especially	neoadjuvant	chemotherapy	in	HER2	positive	and	TN	
breast	cancer	is	common	clinical	practice,	but	high-risk	hormone	receptor	positive	HER2	
negative	patients	with	tumours	showing	a	high	proliferation	rate	or	further	risk	factors	such	
as	grade	3	or	high	risk	classification	based	on	a	multigene	assay	may	benefit	from	cytotoxic	
therapy	and	are	therefore	also	potential	candidates	for	neoadjuvant	chemotherapy7.	
Achieving	a	pathological	complete	response	(pCR)	is	considered	to	indicate	a	favourable	
prognosis	8.	These	considerations	have	led	to	an	increasing	number	of	patients	receiving	
neoadjuvant	systemic	therapy	before	breast	surgery.		
Patients	receiving	neoadjuvant	systemic	therapy	have	a	higher	risk	of	local	and	distant	
recurrence	because	they	are	representing	a	cohort	with	an	unfavourable	tumour	biology.	
Based	on	the	hypothesis	that	these	high-risk	patients	might	benefit	from	the	better	disease	
control	achieved	by	intraoperative	radiotherapy	as	a	boost	as	mentioned	above,	several	
groups	have	investigated	this	approach.	Electrons	as	an	intraoperative	boost	(IOERT)	after	
primary	systemic	therapy	were	found	to	achieve	excellent	local	control	rates	and	a	trend	for	
superiority	compared	to	a	cohort	receiving	an	external	boost	9.	First	data	for	the	use	of	IORT	
with	the	50kV	X-ray	source	in	this	indication	have	been	presented	by	our	study	group	in	
2015	showing	a	favourable	outcome	in	a	one	arm	observational	design	10.		
A	previous	study	from	our	group	including	116	patients	showed	a	statistically	beneficial	
effect	of	TARGIT-IORT	on	OS	but	not	DFS	after	neoadjuvant	chemotherapy	compared	to	an	
external	boost	11.	Although	these	data	have	to	be	interpreted	with	caution	because	of	the	
retrospective	design	of	the	study	and	the	small	size	of	the	cohorts	they	may	be	interpreted	
as	a	signal	of	non-inferiority	of	TARGIT-IORT	as	an	intraoperative	boost.	An	analysis	of	the	
subset	of	patients	at	highest	risk	with	triple	negative	and	HER2	positive	tumours	from	this	
cohort	showed	a	similar	result	for	DFS	but	only	a	trend	for	a	better	OS	without	reaching	
statistical	significance	12.	Based	on	these	results	we	hypothesized	that	the	effect	especially	
on	OS	in	the	unselected	cohort	was	driven	by	the	hormone	receptor	positive	HER2	negative	
subgroup	since	the	local	recurrence	rate	after	neoadjuvant	chemotherapy	shows	significant	
differences	according	to	tumor	biology	and	in	our	rather	short	follow	up	of	49	months	a	
difference	in	local	control	for	a	subgroup	representing	luminal	tumors	was	rather	
improbable	(Jwa	E,	Shin	KH,	Kim	JY	et	al.	(2016)	Locoregional	Recurrence	by	Tumor	Biology	
in	Breast	Cancer	Patients	after	Preoperative	Chemotherapy	and	Breast	Conservation	
Treatment.	Cancer	Res	Treat.	2016	Oct;48(4):1363-1372.).	Here	we	are	presenting	the	
results	for	this	subgroup.	
	
Material	and	methods	
	
Patients	
TARGeted	Intraoperative	radioTherapy	(TARGIT-IORT)	was	introduced	at	the	Marienhospital,	
Bottrop,	Germany,	in	2010	and	from	April	2010	all	patients	undergoing	breast-conserving	
therapy	after	neoadjuvant	chemotherapy	were	treated	with	TARGIT-IORT	boost	(20	Gy	to	
the	surface	of	the	applicator)	during	their	surgery.		The	use	of	IORT	as	an	intraoperative	
boost	was	performed	according	to	the	national	guidelines	in	Germany.	Patients	were	
counselled	considering	use	of	IORT	by	a	radiooncologist	and	a	breast	surgeon	in	an	
interdisciplinary	setting.	All	patients	gave	their	informed	consent.	The	local	ethics	committee	
approved	retrospective	analysis	of	the	data.	
We	performed	a	longitudinal	non-randomised	retrospective	cohort	study	based	upon	data	
from	the	centre	database	including	21	consecutive	patients	with	hormone	receptor	positive	
and	HER2	negative	tumors	treated	between	April	2010	and	November	2011	as	the	
experimental	TARGIT	group.	The	control	group	consists	of	25	consecutive	patients	treated	
with	breast	conserving	therapy	after	neo-adjuvant	chemotherapy	in	the	previous	13	months	
(396	days).	Hormone	receptor	positive	tumours	were	defined	as	more	than	0%	stained	cells	
in	immunohistochemistry	for	oestrogen	and	progesterone	receptor	and	HER2	negative	
either	by	0	or	1+	in	immunohistochemistry	or	2+	and	negative	by	fluorescence	in-situ	
hybridization.	Postoperative	external	beam	radiotherapy	(EBRT)	boost	was	given	to	all	
patients	in	the	control	EBRT	group	with	16	Gy	in	8	fractions.	All	patients	in	both	groups	
received	whole	breast	radiotherapy	with	50	Gy	in	25	fractions.	Radiotherapy	to	the	
supraclavicular	lymph	nodes	was	given	to	all	patients	with	4	or	more	histologically	proven	
positive	lymph	nodes	(positive	either	before	or	after	neoadjuvant	chemotherapy).	Positive	
lymph	nodes	were	confirmed	with	either	a	sentinel	lymph	node	biopsy	or	core	cut	biopsy	
performed	before	the	start	of	neo-adjuvant	chemotherapy.	Patients	with	positive	nodes	
received	an	axillary	dissection	when	the	patient	had	surgery	after	neoadjuvant	
chemotherapy.	
A	titanium	clip	was	placed	in	all	tumours	previous	to	neoadjuvant	chemotherapy	and	the	
localisation	of	the	original	tumour	bed	prior	to	surgery	was	performed	using	a	needle	placed	
under	control	either	by	mammography	(in	the	patients	with	a	clinical	complete	remission)	or	
sonography	(in	the	patients	with	sonographically	detectable	residual	disease).	All	specimens	
underwent	intraoperative	radiography	with	identification	of	the	titanium	clip.	In	the	patients	
of	the	control	group	with	a	planned	external	boost	5	clips	representing	all	levels	of	the	
tumour	bed	were	placed	intraoperatively.		
Pathological	complete	response	(pCR)	in	this	study	was	defined	as	no	residual	invasive	or	
non-invasive	tumour	in	breast	or	lymph	nodes.	All	patients	in	this	study	had	negative	
margins	after	definitive	surgery	defined	as	“no	tumour	touching	ink”	and	all	patients	
received	adjuvant	endocrine	therapy,	postmenopausal	patients	received	an	aromatase	
inhibitor,	premenopausal	patients	younger	than	40	received	a	GnRH	analogue	and	tamoxifen	
and	premenopausal	patients	older	than	40	received	tamoxifen.	All	patients	received	the	
same	neoadjuvant	chemotherapy	regimen	consisting	of	4	cycles	epirubicin	and	
cyclophosphamide	(EC)	followed	by	12	weeks	of	weekly	paclitaxel.	
	
	
Statistical	analysis:	
Follow-up	for	each	patient	was	censored	in	the	control	group	by	396	days	in	order	to	ensure	
that	the	follow	up	of	the	TARGIT	and	EBRT	groups	remained	similar.	This	exclusion	of	
additional	13	months	of	follow	up	led	to	just	one	event	being	excluded	from	the	EBRT	group.	
Therefore,	we	believe	that	this	methodology	would	not	change	the	results	of	the	analysis	
and	at	the	same	time	counter	the	criticism	of	potentially	unequal	follow-up	between	the	
groups.		
Age	and	tumour	size	in	mm	were	compared	using	the	t-test.	Categorical	variables	of	grade,	
lymph	node	positivity	and	pathological	complete	response	rate	were	compared	using	the	
Chi-square	and	Fisher’s	Exact	test.	
The	following	survival	outcomes	were	analysed	and	compared	between	the	TARGIT-Boost	
and	EBRT-Boost	groups:	a)	Overall	mortality	(OM),	event	=	any	death,		b)	breast	cancer	
specific	mortality	(BCSM),	event	=	breast	cancer	death,	and	c)	non-breast-cancer	mortality	
(NBCSM),	event=death	from	causes	other	than	breast	cancer,	d)	disease-free	survival	(DFS),	
event	=	any	relapse	or	death	For	all	outcomes	patients	were	censored	at	the	time	of	last	
follow	up.	Kaplan-Meier	curves	were	plotted	and	we	estimated	outcomes	at	the	5-year	time	
point.	
All	of	the	tests	were	two-sided,	and	a	p-value	of	<	0.05	was	regarded	as	statistically	
significant.	The	software	used	was:	the	R	system	for	statistical	computing	(version	3.0.1;	R	
Development	Core	Team,	Vienna,	Austria,	2013),	and	STATA	(version	14.0).	
	
Results	
Median	follow-up	was	49	months	for	both	cohorts.	No	subject	was	lost	to	follow-up.	
Characteristics	of	the	study	population	are	shown	in	table	1.	Age	at	the	time	of	first	
diagnosis	was	the	only	significant	difference	between	the	two	cohorts	with	the	TARGIT	
cohort	being	significantly	younger	than	the	EBRT	cohort.	The	toxicity	data	for	the	cohort	
from	which	the	experimental	group	receiving	TARGIT-IORT	as	a	boost	after	neoadjuvant	
chemotherapy	was	extracted	have	been	reported	before	and	were	comparable	with	the	
average	postoperative	morbidity	after	breast	conserving	surgery	in	our	institution	(10).	
There	was	no	statistically	significant	difference	between	TARGIT	and	EBRT	in	terms	of	
disease	free	survival	and	breast-cancer-specific	mortality	although	TARGIT	fared	numerically	
better	than	EBRT	regarding	these	variables.	Overall	mortality	was	lower	by	21%	with	TARGIT.	
This	result	and	the	difference	in	non-breast-cancer-specific	mortality	of	16%	were	
statistically	significant.	
Kaplan-Meier	curves	and	p-values	can	be	found	in	figures	1	to	4.	
	
Age	(years)	 IORT+	 IORT-	 	 p-value	 	
N	 21	 25	 	 	 	
Mean	 51.381	 60.2	 	 	 	
Sd	 10.84	 11.453	 	 0.011	 	
	 	 	 	 	 	
Tumour	
Size	(mm)	 IORT+	 IORT-	 	 	 	
N	 21	 25	 	 	 	
Mean	 26	 27.84	 	 	 	
Sd	 11.6276	 9.5029	 	 0.558	 	
	 	 	 	 	 	
Grading	 G1	 G2	 G3	 	 	
IORT+	 0	 13	 8	 	 	
IORT-	 1	 14	 10	 1	
Fishers	
Exact	
	 	 	 	 	 	
Node		 Pos	 Neg	 	 	 	
IORT+	 14	 7	 	 	 	
IORT-	 16	 9	 	 1	
Fishers	
Exact	
	 	 	 	 	 	
pCR	 Pos	 Neg	 	 	 	
IORT+	 4	 17	 	 	 	
IORT-	 3	 18	 	 1	
Fishers	
Exact	
	
Table	1:	Patient	and	tumour	characteristics		
	
	
Figure	1:	Disease	free	survival	
	
	
Figure	2:	Overall	mortality	
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Figure	3:	Breast-cancer-specific	mortality	
	
	
Figure	4:	Non-breast-cancer-specific	mortality	
	
	
Discussion	
Initial	reports	about	patients	treated	with	TARGIT-	IORT	as	an	intraoperative	boost	during	
breast	conserving	operations	suggested	that	it	might	achieve	superior	local	control	3	4.	This	
approach	has	become	a	standard	in	several	breast	cancer	centres	particularly	in	Germany	
and	the	United	States.	In	an	attempt	of	de-escalation	TARGIT-IORT	was	tested	as	the	only	
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radiotherapy	in	the	course	of	breast	conserving	therapy	and	has	been	found	non-inferior	to	
external	whole	breast	irradiation	in	selected	patients	in	a	risk	adapted	approach	in	the	
TARGIT	A	trial	1.	There	has	been	concern	regarding	a	possible	higher	rate	of	breast	fibrosis	
found	with	TARGIT-IORT.	An	analysis	of	the	TARGIT	A	population	demonstrated	a		rate	of	
breast	fibrosis	within	the	range	seen	with	EBRT	alone	13.	In	previous	studies	of	our	group	we	
found	that	adapting	this	approach	among	patients	who	were	undergoing	breast	conserving	
therapy	after	neoadjuvant	systemic	therapy	does	not	compromise	cosmetic	outcome	14,		
does	not	interfere	with	pathological	evaluation	of	the	margins	and	does	not	alter	re-excision	
rates	15.		
Patients	who	are	candidates	for	neoadjuvant	therapy	are	generally	at	high	risk	of	local	and	
distant	relapse	and	of	death	from	breast	cancer	16	17.	A	retrospective	analysis	using	a	
different	technique	of	intraoperative	radiotherapy	–	Intraoperative	Electron	radiotherapy	
(IOERT)	-	compared	83	patients	receiving	IOERT	after	neoadjuvant	therapy	with	a	group	of	
26	patients	receiving	conventional	EBRT	boost	and	found	a	trend	for	superiority	for	IOERT	9.		
	
In	the	non-randomized	retrospective	cohort	analysis	presented	here	we	compared	
intraoperative	tumour	bed	boost	with	a	50kV	X-ray	device	with	an	external	boost	among	
patients	undergoing	breast	conserving	surgery	after	neoadjuvant	chemotherapy	including	
only	patients	with	hormone	receptor	positive	HER2	negative	tumours.	All	patients	received	
external	beam	whole	breast	irradiation.	The	rationale	for	our	investigation	was	based	on	our	
findings	regarding	the	whole	cohort.	In	this	previous	analysis	patients	receiving	their	boost	
as	TARGIT-IORT	had	a	statistically	significant	better	overall	survival	11.	Based	on	the	
hypothesis	that	this	difference	might	be	attributed	to	the	subset	of	patients	with	the	worst	
prognosis	at	baseline	we	had	then	decided	to	look	at	patients	with	triple	negative	and	HER2	
positive	tumours	specifically.	In	this	analysis	neither	DFS	nor	OS	differed	significantly	
between	patients	receiving	an	external	boost	and	patients	receiving	TARGIT-IORT	although	
trends	favoured	TARGIT-IORT	12.	These	findings	triggered	the	analysis	presented	here	
assuming	the	effect	in	the	unselected	cohort	must	have	been	driven	by	the	hormone	
receptor	positive	HER2	negative	subgroup.		
The	comparator	groups	were	well	balanced	with	age	being	the	only	significant	difference.	Of	
course	this	difference	has	to	be	addressed	regarding	the	significant	difference	in	overall	
survival	driven	by	non-breast-cancer	mortality.	Considering	the	median	follow	up	of	49	
months	the	mean	age	of	51	years	in	the	TARGIT	group	and	60	years	in	the	EBRT	group	will	
probably	not	have	influenced	the	non-breast-cancer	mortality	difference	significantly	since	
the	short	time	survival	probability	is	0.99769726	for	a	female	aged	51	in	Germany	and	of	
0.99471509	for	the	age	of	60	respectively	(www-genesis.destatis.de).		
	
Both	cohorts	received	the	same	chemotherapy	schedules	and	achieved	similar	proportions	
of	pathological	complete	response.	Endocrine	therapies	according	to	menopausal	status	
were	the	same	for	both	groups.	However,	even	though	we	found	no	significant	difference	in	
patient	characteristics	between	the	two	cohorts,	a	selection	bias	cannot	be	excluded	
because	this	was	not	a	randomised	trial.		
In	the	TARGIT-A	study	1	a	trend	for	superior	overall	survival	with	TARGIT-IORT	compared	
with	EBRT	was	observed.	This	was	mainly	attributable	to	reduced	mortality	from	causes	
other	than	breast	cancer.	It	has	been	suggested	that	the	favourable	effects	of	IORT	on	
surgical	wound	fluid	may	result	in	wider	systemic	beneficial	effects	that	may	have	
contributed	to	the	reduced	mortality	seen	in	the	TARGIT-A	trial.	A	non-randomised	
comparison	of	those	patients	in	the	TARGIT-A	trial	who	received	IORT	+	EBRT	versus	those	
who	received	EBRT	found	a	statistically	significant	reduction	in	non-breast-cancer	mortality.	
There	were	no	deaths	from	non-breast	cancer	causes	in	the	IORT+EBRT	group	compared	
with	24	in	the	EBRT	group	0/218	vs	24/892,	log-rank	p	=	0.012	18.	An	explanation	the	authors	
suggested	for	this	phenomenon	was	a	potential	influence	of	immediate	IORT	on	local	
tumour	microenvironment	and	wound	fluid	that	could	get	absorbed	and	cause	systemic	
beneficial	effects.	Tumour	cell	line	experiments	have	shown	that	the	stimulating	effect	of	
wound	fluid	after	lumpectomy	on	breast	cancer	cell	proliferation,	motility	and	invasiveness	
is	abrogated	if	the	patient	receives	IORT	during	the	lumpectomy	19.	An	analysis	of	the	same	
study	group	demonstrated	an	induction	of	miR-223	in	the	peritumoral	breast	tissue	resulting	
in	a	downregulation	of	the	local	expression	of	epidermal	growth	factor	(EGF)	and	a	
decreased	activation	of	epidermal	growth	factor	receptor	(EGFR)	after	IORT	as	a	possible	
explanation	for	this	effect	20.	It	has	also	previously	been	discussed	that	IORT	during	
lumpectomy	may	be	changing	the	systemic	course	of	not	just	breast	cancer	but	also	that	of	
ischemic	heart	disease	for	the	better	21.		Another	explanation	of	the	general	effects	of	
intraoperative	radiotherapy	could	be	a	possible	influence	on	factors	of	tumour	immunology	
such	as	“programmed	death	1”	(PD-1,	ligands	PD-L1	and	PD-L2)	and	“cytotoxic	T-lymphocyte	
antigen	4”	(CTLA-4,	ligands	CD80	und	CD	86)	due	to	the	localized	character	of	the	therapy.	
There	are	signals	that	local	therapies	may	play	a	role	in	the	presentation	of	tumour	cells	as	
antigens	to	the	immune	system	thus	triggering	generalized	immunological	responses.	
Investigations	on	the	use	of	high	focused	ultrasound	applied	to	tumours	for	example	showed	
an	increased	accumulation	of	natural	killer	cells	within	the	tumour	22.		
The	outcome	data	reported	from	our	group	before	11	and	reproduced	in	the	subgroup	
analysis	presented	here	seem	to	support	the	hypothesis	that	the	benefit	of	IORT	may	not	be	
limited	to	a	local	effect	by	simply	avoiding	a	geographic	miss.	The	significantly	better	overall	
survival	in	the	unselected	cohort	as	well	as	in	the	hormone	receptor	positive	HER2	negative	
subgroup	was	driven	by	the	significantly	better	non-breast-cancer	specific	mortality.	As	
mentioned	above	a	similar	effect	was	demonstrated	in	the	TARGIT-A	study	in	the	whole	
study	population	1	as	well	as	in	the	subgroup	of	patients	receiving	whole	breast	irradiation	
after	IORT,	i.e.	receiving	the	same	therapy	as	our	study	population	18.	
	
Due	to	the	retrospective	character	of	our	trial	we	are	recommending	a	cautious	
interpretation	of	these	data,	but	still	our	findings	confirm	that	the	use	of	TARGIT-IORT	as	a	
boost	is	yielding	results	not	worse	than	external	boost	irradiation.	Regarding	the	supposed	
beneficial	effect	of	TARGIT-IORT	on	non-breast-cancer-specific	mortality	more	research	is	
needed.	We	are	planning	a	matched-pairs	analysis	of	our	dataset	of	the	more	than	700	cases	
treated	at	our	institution	with	TARGIT-IORT	as	an	intraoperative	boost	yet	compared	with	
cases	treated	with	an	external	boost	with	a	focus	on	comorbidities	at	baseline	and	non-
breast-cancer-specific	morbidity	and	mortality	and	the	influence	of	tumour	biology.		
Furthermore	the	hypothesis	of	possible	systemic	beneficial	effects	of	IORT	will	be	
prospectively	tested	in	the	randomised	TARGIT-B	trial	comparing	TARGIT-IORT	boost	to	an	
external	boost	in	women	who	are	either	younger	than	45	or	have	a	higher	risk	of	local	
recurrence.	This	trial	is	including	a	stratification	for	the	use	of	neoadjuvant	chemotherapy	
and	planned	subgroup	analyses	regarding	tumour	biology.	We	encourage	active	
participation	in	the	TARGIT-B	trial.		
	
Conclusion	
	
In	a	previous	analysis	we	demonstrated	non-inferior	and	numerically	superior	overall	
survival	attributable	to	a	lower	non-breast-cancer	mortality	for	TARGIT-IORT	during	
lumpectomy	after	neoadjuvant	chemotherapy	as	a	tumour	bed	boost	compared	to	an	
external	beam	radiotherapy	boost	in	an	unselected	population.	In	our	current	analysis	we	
could	show	that	this	difference	is	driven	by	the	hormone	receptor	positive	HER2	negative	
subgroup,	although	we	acknowledge	that	our	results	have	to	be	interpreted	with	caution	
due	to	a	possible	selection	bias,	the	comparatively	small	sample	size	and	a	rather	short	
follow-up	for	a	hormone	receptor	positive	cohort.	These	data	give	further	support	to	the	
inclusion	of	such	patients	in	the	randomised	TARGIT-B	trial	testing	whether	IORT	boost	is	
superior	to	EBRT	boost	and	the	analysis	of	subgroups	based	on	tumour	biology	in	this	trial.	
Furthermore	our	results	are	warranting	further	investigation	on	effects	of	TARGIT-IORT	on	
non-breast-cancer-specific	endpoints.	
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